Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1992 Mar;87(3):493-8.
doi: 10.1111/j.1365-2249.1992.tb03025.x.

IL-2 infusion abrogates humoral immune responses in humans

Affiliations

IL-2 infusion abrogates humoral immune responses in humans

D J Gottlieb et al. Clin Exp Immunol. 1992 Mar.

Abstract

Although IL-2 infusion enhances cell-mediated cytotoxicity in patients with neoplastic disease, administration is paradoxically associated with a modest fall in total serum IgG and an increased risk of infection. We now show that the adverse effects of IL-2 infusion on the humoral immune system are substantial. Although IL-2 induces the B cell growth and differentiating factors IL-4 and IL-6, infusion abrogates primary antibody responses entirely and reduces secondary antibody responses 50-fold following antigen challenge. There is no evidence of the generation of cells with suppressive activity on B cells but IL-2 increases the ratio of circulating virgin:memory cells. These results may help to explain the increased rate of bacterial infection in patients receiving IL-2. As IL-2 plays a central role in the generation of an immune response, the finding that it is also sufficiently immunosuppressive to inhibit primary- and secondary-type antibody responses suggests that exploration of the underlying mechanisms may provide insights into immune system homeostasis and may offer new approaches to therapeutic immunosuppression.

PubMed Disclaimer

Similar articles

Cited by

References

    1. J Immunol. 1986 May 15;136(10):3513-6 - PubMed
    1. Lancet. 1986 Feb 15;1(8477):339-43 - PubMed
    1. N Engl J Med. 1987 Apr 9;316(15):889-97 - PubMed
    1. Eur J Immunol. 1987 Oct;17(10):1411-6 - PubMed
    1. J Exp Med. 1984 Nov 1;160(5):1450-66 - PubMed

MeSH terms